Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Oct 1;50(10):e744-e758.
doi: 10.1097/CCM.0000000000005627. Epub 2022 Jul 27.

Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19

Neha Gupta  1 , Lisa Settle  2 , Brent R Brown  3 , Donna L Armaignac  4 , Michael Baram  5 , Nicholas E Perkins  6 , Margit Kaufman  7 , Roman R Melamed  8 , Amy B Christie  9 , Valerie C Danesh  10 , Joshua L Denson  11 , Sreekanth R Cheruku  12 , Karen Boman  13 , Vikas Bansal  14 , Vishakha K Kumar  13 , Allan J Walkey  15 , Juan P Domecq  16 , Rahul Kashyap  14 , Christopher E Aston  17 ; Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator Group
Collaborators, Affiliations
Observational Study

Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19

Neha Gupta et al. Crit Care Med. .

Abstract

Objectives: To determine the association of prior use of renin-angiotensin-aldosterone system inhibitors (RAASIs) with mortality and outcomes in hospitalized patients with COVID-19.

Design: Retrospective observational study.

Setting: Multicenter, international COVID-19 registry.

Subjects: Adult hospitalized COVID-19 patients on antihypertensive agents (AHAs) prior to admission, admitted from March 31, 2020, to March 10, 2021.

Interventions: None.

Measurements and main results: Data were compared between three groups: patients on RAASIs only, other AHAs only, and those on both medications. Multivariable logistic and linear regressions were performed after controlling for prehospitalization characteristics to estimate the effect of RAASIs on mortality and other outcomes during hospitalization. Of 26,652 patients, 7,975 patients were on AHAs prior to hospitalization. Of these, 1,542 patients (19.3%) were on RAASIs only, 3,765 patients (47.2%) were on other AHAs only, and 2,668 (33.5%) patients were on both medications. Compared with those taking other AHAs only, patients on RAASIs only were younger (mean age 63.3 vs 66.9 yr; p < 0.0001), more often male (58.2% vs 52.4%; p = 0.0001) and more often White (55.1% vs 47.2%; p < 0.0001). After adjusting for age, gender, race, location, and comorbidities, patients on combination of RAASIs and other AHAs had higher in-hospital mortality than those on RAASIs only (odds ratio [OR] = 1.28; 95% CI [1.19-1.38]; p < 0.0001) and higher mortality than those on other AHAs only (OR = 1.09; 95% CI [1.03-1.15]; p = 0.0017). Patients on RAASIs only had lower mortality than those on other AHAs only (OR = 0.87; 95% CI [0.81-0.94]; p = 0.0003). Patients on ACEIs only had higher mortality compared with those on ARBs only (OR = 1.37; 95% CI [1.20-1.56]; p < 0.0001).

Conclusions: Among patients hospitalized for COVID-19 who were taking AHAs, prior use of a combination of RAASIs and other AHAs was associated with higher in-hospital mortality than the use of RAASIs alone. When compared with ARBs, ACEIs were associated with significantly higher mortality in hospitalized COVID-19 patients.

Trial registration: ClinicalTrials.gov NCT04323787.

PubMed Disclaimer

Conflict of interest statement

Dr. Perkins received funding from TelmedIQ. Dr. Kaufman’s institution received funding from the Society of Critical Care Medicine, and she received funding from consulting for Mendaera. Dr. Christie’s institution received funding from Navicent Health Foundation. Ms. Boman, Drs. Kumar’s, Walkey’s, and Kashyap’s institutions received funding from the Gordon and Betty Moore Foundation. Ms. Boman, Drs. Kumar’s, and Kashyap’s institutions received funding from Janssen R & D. Dr. Aston’s institution received funding from the National Institutes of Health. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Flow chart of patients in each group after applying exclusion and inclusion criteria.
Figure 2.
Figure 2.
Cox proportional-hazards model comparing survival probability of patients on renin-angiotensin-aldosterone system inhibitors (RAASIs) only, RAASIs and other antihypertensive agents (AHAs) and other AHAs only. Survival time is from hospital admission to death; if the patient did not die, then survival time is right censored at time of discharge from hospital.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Rossi GP, Sanga V, Barton M: Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife 2020; 9:e57278. - PMC - PubMed
    1. Furuhashi M, Moniwa N, Mita T, et al. : Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens 2015; 28:15–21 - PubMed
    1. Zheng Z, Peng F, Xu B, et al. : Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis J Infect 2020; 81:e16–e25 - PMC - PubMed
    1. Fernández-Ruiz I: RAAS inhibitors do not increase the risk of COVID-19. Nat Rev Cardiol 2020; 17:383. - PMC - PubMed
    1. Morales DR, Conover MM, You SC, et al. : Renin-angiotensin system blockers and susceptibility to COVID-19: An international, open science, cohort analysis. Lancet Digit Health 2021; 3:e98-e114 - PMC - PubMed

Publication types

Substances

Associated data